Our ability to use engineered bacteria for cancer therapy is rapidly expanding. A survey of preclinical, clinical and commercial efforts provides an overview of the state of the field, revealing trends that could inform future directions.
- Edward R. Ballister
- Alexander Michels
- Tal Danino
